SPDR S&P Biotech ETF (XBI)
| 150.27 Data as of 3:59pm ET |  +9.65 / +6.86%Today’s Change | 113.22 Today|||52-Week Range 172.52 | +15.41% Year-to-Date |
Investment Objective
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Latest XBI News
| Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox Jul 18 / TheStreet.com | Which Matters More: Janet Yellen Or Earnings & Economic Data? Jul 16 / Benzinga |
| A Signal to Be Greedy Jul 17 / TheStreet.com |
Performance
| 1 month | -8.39% | 3 years | +23.48% | |
| 3 months | +5.23% | 5 years | +23.36% | |
| 1 year | +17.30% | Since inception | +13.45% |
Data through 07/23/2014
Quote Details
| Previous close | $140.62 |
| Open day’s range | 147.64 – 150.99 |
| Net asset value (NAV) | 140.68 (07/22/2014) |
| Daily volume | 956,286 |
| Average volume (3 months) | 588,620 |
Data as of 3:59pm ET, 07/23/2014
Peer Comparisonvs. Health ETFs
| XBI | Category | |
|---|---|---|
| Performance 5-yr return | +23.36% | +24.14% |
| Expense Gross exp ratio | 0.35% | 0.43% |
| Risk 5 year sharpe ratio | 1.02 | 1.52 |
| Net assets | $1.1B | $1.4B |
| Average market cap | $1.9B | $25.9B |
| Average P/E | -- | 26.1 |
| Dividend / Share | -- | 0.21% |
Competitors
| VHT Vanguard Health Care ETF |
| XLV Health Care Select Sector SPDR® Fund |
| IXJ iShares Global Healthcare ETF |
Holdings
Top 5 SectorsPortfolio weighting
| Healthcare | 100.00% |
| Business service | 0.00% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
Top 10 HoldingsPortfolio weighting
| INSM Insmed Inc | 1.98% |
| VRTX Vertex Pharmaceuticals Inc | 1.59% |
| GEVA Synageva BioPharma Corp | 1.55% |
| INO Inovio Pharmaceuticals Inc | 1.53% |
| ONVO Organovo Holdings Inc | 1.49% |
| NLNK NewLink Genetics Corp | 1.45% |
| ARWR Arrowhead Research Corp | 1.43% |
| RGEN Repligen Corp | 1.42% |
| DYAX Dyax Corp | 1.41% |
| VNDA Vanda Pharmaceuticals Inc | 1.40% |
.
